Titre : Granulocytes

Granulocytes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Integrin beta3
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Granulocytes : Questions médicales les plus fréquentes", "headline": "Granulocytes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Granulocytes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-22", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Granulocytes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Leucocytes", "url": "https://questionsmedicales.fr/mesh/D007962", "about": { "@type": "MedicalCondition", "name": "Leucocytes", "code": { "@type": "MedicalCode", "code": "D007962", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A15.382.490" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Granulocytes basophiles", "alternateName": "Basophils", "url": "https://questionsmedicales.fr/mesh/D001491", "about": { "@type": "MedicalCondition", "name": "Granulocytes basophiles", "code": { "@type": "MedicalCode", "code": "D001491", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A15.382.490.315.120" } } }, { "@type": "MedicalWebPage", "name": "Granulocytes éosinophiles", "alternateName": "Eosinophils", "url": "https://questionsmedicales.fr/mesh/D004804", "about": { "@type": "MedicalCondition", "name": "Granulocytes éosinophiles", "code": { "@type": "MedicalCode", "code": "D004804", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A15.382.490.315.251" } } } ], "about": { "@type": "MedicalCondition", "name": "Granulocytes", "alternateName": "Granulocytes", "code": { "@type": "MedicalCode", "code": "D006098", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Cathy Conry-Cantilena", "url": "https://questionsmedicales.fr/author/Cathy%20Conry-Cantilena", "affiliation": { "@type": "Organization", "name": "Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD." } }, { "@type": "Person", "name": "Michael Gruber", "url": "https://questionsmedicales.fr/author/Michael%20Gruber", "affiliation": { "@type": "Organization", "name": "Department of Anesthesiology, University Hospital Regensburg, Raubling, Germany." } }, { "@type": "Person", "name": "Hans-Uwe Simon", "url": "https://questionsmedicales.fr/author/Hans-Uwe%20Simon", "affiliation": { "@type": "Organization", "name": "Institute of Pharmacology, University of Bern, Bern, Switzerland; email: thomas.kaufmann@pki.unibe.ch, hans-uwe.simon@pki.unibe.ch." } }, { "@type": "Person", "name": "Yu Hao", "url": "https://questionsmedicales.fr/author/Yu%20Hao", "affiliation": { "@type": "Organization", "name": "Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, China." } }, { "@type": "Person", "name": "Can Zhang", "url": "https://questionsmedicales.fr/author/Can%20Zhang", "affiliation": { "@type": "Organization", "name": "Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "SINE-VNTR-Alu retrotransposon insertion as a novel mutational event underlying Glanzmann thrombasthenia.", "datePublished": "2023-08-20", "url": "https://questionsmedicales.fr/article/37604334", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jtha.2023.08.012" } }, { "@type": "ScholarlyArticle", "name": "Monodispersity Increases Adhesion Efficiency and Specificity for Ultrasound-Targeted Microbubbles.", "datePublished": "2022-09-26", "url": "https://questionsmedicales.fr/article/36153974", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acsbiomaterials.2c00528" } }, { "@type": "ScholarlyArticle", "name": "Sortase A-mediated cyclization of novel polycyclic RGD peptides for α", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35839966", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bmcl.2022.128888" } }, { "@type": "ScholarlyArticle", "name": "Profiling target engagement and cellular uptake of cRGD-decorated clinical-stage core-crosslinked polymeric micelles.", "datePublished": "2022-07-11", "url": "https://questionsmedicales.fr/article/35816231", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s13346-022-01204-8" } }, { "@type": "ScholarlyArticle", "name": "microRNA-25-3p suppresses osteogenic differentiation of BMSCs in patients with osteoporosis by targeting ITGB3.", "datePublished": "2022-06-28", "url": "https://questionsmedicales.fr/article/35777302", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.acthis.2022.151926" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Systèmes sanguin et immunitaire", "item": "https://questionsmedicales.fr/mesh/D006424" }, { "@type": "ListItem", "position": 3, "name": "Système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007107" }, { "@type": "ListItem", "position": 4, "name": "Leucocytes", "item": "https://questionsmedicales.fr/mesh/D007962" }, { "@type": "ListItem", "position": 5, "name": "Granulocytes", "item": "https://questionsmedicales.fr/mesh/D006098" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Granulocytes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Granulocytes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Granulocytes", "description": "Comment diagnostiquer une granulocytopénie ?\nQuels tests pour évaluer les granulocytes ?\nQuels signes indiquent une infection liée aux granulocytes ?\nComment évaluer la fonction des granulocytes ?\nQuel rôle joue la biopsie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D006098?mesh_terms=Integrin+beta3&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Granulocytes", "description": "Quels symptômes d'une carence en granulocytes ?\nComment se manifeste une réaction allergique ?\nQuels symptômes d'une inflammation ?\nQuels signes d'une infection bactérienne ?\nQuels symptômes d'une leucémie ?", "url": "https://questionsmedicales.fr/mesh/D006098?mesh_terms=Integrin+beta3&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Granulocytes", "description": "Comment prévenir les infections chez les patients à faible granulocytes ?\nQuels vaccins sont recommandés ?\nComment éviter les complications liées aux granulocytes ?\nQuel rôle de l'alimentation dans la prévention ?\nComment gérer le stress pour la santé des granulocytes ?", "url": "https://questionsmedicales.fr/mesh/D006098?mesh_terms=Integrin+beta3&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Granulocytes", "description": "Comment traiter une granulocytopénie ?\nQuels médicaments stimulent les granulocytes ?\nComment traiter une infection liée aux granulocytes ?\nQuel rôle des corticostéroïdes dans le traitement ?\nQuand envisager une greffe de moelle osseuse ?", "url": "https://questionsmedicales.fr/mesh/D006098?mesh_terms=Integrin+beta3&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Granulocytes", "description": "Quelles complications d'une granulocytopénie sévère ?\nQuels risques d'une leucémie myéloïde ?\nComment les granulocytes affectent-ils la cicatrisation ?\nQuelles sont les complications des traitements immunosuppresseurs ?\nQuels effets secondaires des médicaments sur les granulocytes ?", "url": "https://questionsmedicales.fr/mesh/D006098?mesh_terms=Integrin+beta3&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Granulocytes", "description": "Quels facteurs augmentent le risque d'infections ?\nQuel rôle des maladies auto-immunes ?\nComment le tabagisme affecte-t-il les granulocytes ?\nQuels risques liés à l'exposition aux produits chimiques ?\nQuel impact de la génétique sur les granulocytes ?", "url": "https://questionsmedicales.fr/mesh/D006098?mesh_terms=Integrin+beta3&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une granulocytopénie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un hémogramme révèle une diminution des granulocytes dans le sang." } }, { "@type": "Question", "name": "Quels tests pour évaluer les granulocytes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins comme la numération formule sanguine sont utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une infection liée aux granulocytes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, fatigue et inflammation peuvent signaler une infection." } }, { "@type": "Question", "name": "Comment évaluer la fonction des granulocytes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de phagocytose et de dégranulation peuvent être réalisés." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie médullaire peut aider à évaluer la production de granulocytes." } }, { "@type": "Question", "name": "Quels symptômes d'une carence en granulocytes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Infections fréquentes, fièvre et fatigue sont des symptômes courants." } }, { "@type": "Question", "name": "Comment se manifeste une réaction allergique ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Éruptions cutanées, démangeaisons et œdème peuvent survenir." } }, { "@type": "Question", "name": "Quels symptômes d'une inflammation ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Rougeur, chaleur, gonflement et douleur sont des signes d'inflammation." } }, { "@type": "Question", "name": "Quels signes d'une infection bactérienne ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons et douleur localisée peuvent indiquer une infection." } }, { "@type": "Question", "name": "Quels symptômes d'une leucémie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, ecchymoses et infections fréquentes peuvent être présents." } }, { "@type": "Question", "name": "Comment prévenir les infections chez les patients à faible granulocytes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir une bonne hygiène et éviter les foules sont essentiels." } }, { "@type": "Question", "name": "Quels vaccins sont recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccins contre la grippe et le pneumocoque sont souvent conseillés." } }, { "@type": "Question", "name": "Comment éviter les complications liées aux granulocytes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Surveiller les signes d'infection et consulter rapidement un médecin." } }, { "@type": "Question", "name": "Quel rôle de l'alimentation dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée renforce le système immunitaire." } }, { "@type": "Question", "name": "Comment gérer le stress pour la santé des granulocytes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation peuvent aider à réduire le stress." } }, { "@type": "Question", "name": "Comment traiter une granulocytopénie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des transfusions de granulocytes ou des médicaments stimulants peuvent être utilisés." } }, { "@type": "Question", "name": "Quels médicaments stimulent les granulocytes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le filgrastim et le pegfilgrastim sont des agents couramment utilisés." } }, { "@type": "Question", "name": "Comment traiter une infection liée aux granulocytes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des antibiotiques sont prescrits pour traiter les infections bactériennes." } }, { "@type": "Question", "name": "Quel rôle des corticostéroïdes dans le traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire l'inflammation et moduler la réponse immunitaire." } }, { "@type": "Question", "name": "Quand envisager une greffe de moelle osseuse ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "En cas de maladies graves affectant la production de granulocytes." } }, { "@type": "Question", "name": "Quelles complications d'une granulocytopénie sévère ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Infections graves, septicémie et complications hémorragiques peuvent survenir." } }, { "@type": "Question", "name": "Quels risques d'une leucémie myéloïde ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Risque accru d'infections et de saignements en raison de la production anormale." } }, { "@type": "Question", "name": "Comment les granulocytes affectent-ils la cicatrisation ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une diminution des granulocytes peut retarder la cicatrisation des plaies." } }, { "@type": "Question", "name": "Quelles sont les complications des traitements immunosuppresseurs ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Infections opportunistes et cancers peuvent survenir avec ces traitements." } }, { "@type": "Question", "name": "Quels effets secondaires des médicaments sur les granulocytes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent entraîner une diminution des granulocytes." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'infections ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Une immunodépression, le diabète et l'âge avancé augmentent le risque." } }, { "@type": "Question", "name": "Quel rôle des maladies auto-immunes ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner une destruction accrue des granulocytes." } }, { "@type": "Question", "name": "Comment le tabagisme affecte-t-il les granulocytes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme peut altérer la fonction des granulocytes et augmenter l'inflammation." } }, { "@type": "Question", "name": "Quels risques liés à l'exposition aux produits chimiques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certains produits chimiques peuvent endommager la moelle osseuse et réduire les granulocytes." } }, { "@type": "Question", "name": "Quel impact de la génétique sur les granulocytes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des prédispositions génétiques peuvent influencer la production et la fonction des granulocytes." } } ] } ] }

Sources (825 au total)

SINE-VNTR-Alu retrotransposon insertion as a novel mutational event underlying Glanzmann thrombasthenia.

Glanzmann thrombasthenia (GT) is an autosomal recessive platelet aggregation disorder caused by mutations in ITGA2B or ITGB3.... We aimed to assess the phenotype and investigate the genetic etiology of a GT pedigree.... A patient with bleeding manifestations and mild mental retardation was enrolled. Complete blood count, coagulation, and platelet aggregation tests were performed. Causal mutations were identified via ... GT was diagnosed in a patient with defective platelet aggregation. Novel compound heterozygous ITGB3 variants were identified, with a maternal nonsense mutation (c.2222G>A, p.Trp741∗) and a paternal S... Novel compound heterozygous ITGB3 mutations were identified in the GT pedigree, resulting in defects of αⅡbβ3 biosynthesis. This is the first report of SVA retrotransposon insertion in the genetic pat...

Effect of c.1431C > T mutation, a causative mutation of Glanzmann's thrombasthenia, on ITGB3 splicing, gene and protein expression.

Recently, it was reported that the non-synonymous c.1431C > T (p. G477=) mutation of the integrin subunit β3 (ITGB3) gene is the cause of Glanzmann's thrombasthenia (GT). However, the functional conse... Peripheral blood samples were collected from Chinese family members (parents and proband and his sister), and DNA was extracted and sequenced using whole-exome and Sanger sequencing. The effect of c.1... Minigene splicing assay showed that c.1431C > T mutation causes three kinds of alternative splicing; (1) a 95 bp deletion in the middle of exon10, (2) a 155 bp deletion (95 bp deletion in the middle o... Due to its significant impact on protein expression, c.1431C > T mutation in ITGB3 could be considered a pathogenic variant of GT. This could enrich the ITGB3 mutation spectrum and provide a base for ...

An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study.

Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associat... To investigate whether a single dose of anti-HPA-1a (1000 IU) could markedly accelerate the elimination of HPA-1ab platelets transfused into healthy, HPA-1a-negative participants as compared with plac... This randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study (EudraCT: 2019-003459-12) included HPA-1a- and HLA-A2-negative healthy men. Cohort 1 received intrave... Twelve participants were allocated to cohort 1 or 1B and randomized to receive RLYB211 (n = 9) or placebo (n = 3). RLYB211 markedly accelerated the elimination of HPA-1ab platelets in all participants... These data support the hypothesis that anti-HPA-1a could be used as prophylaxis in women at risk of having an FNAIT-affected pregnancy....

The Role of TLR-2 in Lethal COVID-19 Disease Involving Medullary and Resident Lung Megakaryocyte Up-Regulation in the Microthrombosis Mechanism.

Patients with COVID-19 have coagulation and platelet disorders, with platelet alterations and thrombocytopenia representing negative prognostic parameters associated with severe forms of the disease a... The aim of this study was to study the expression of platelet glycoprotein IIIa (CD61), playing a critical role in platelet aggregation, together with TRL-2 as a marker of innate immune activation.... A total of 25 patients were investigated, with the majority (24/25, 96%) having co-morbidities and dying from a fatal form of SARS-CoV-2(+) infection (COVID-19+), with 13 men and 12 females ranging in... Microthrombosis in deadly COVID-19+ lung disease is associated with an increase in the number of CD61+ platelets and megakaryocytes in the pulmonary interstitium, as well as their functional activatio...